Ascidian Therapeutics

Company Deals

Ascidian Therapeutics Partners with Eli Lilly in $1.9 Billion RNA Exon Editing Deal for Monogenic Kidney Diseases

Fineline Cube Jun 4, 2026

Ascidian Therapeutics, a US-based biotechnology company pioneering RNA exon editing technology, announced a global research...

Company Drug

Hansoh Pharmaceutical’s Olatorepatide GLP-1/GIP Dual Agonist Accepted for NMPA Review for Weight Management Indication

Company Drug

Johnson & Johnson’s Nipocalimab (Imaavy) Demonstrates Efficacy in Phase II JASMINE Study for Systemic Lupus Erythematosus, First FcRn Blocker to Show Success in SLE

Company Deals

Lundbeck Partners with Cradle to Deploy AI-Guided Protein Engineering for CNS Antibody Discovery

Company Drug

Novo Nordisk Launches Wegovy Oral Tablets in UAE – First International Market Outside US for Semaglutide Weight Management Therapy